Bank OZK Has $2.05 Million Holdings in Aflac Incorporated (NYSE:AFL)

Bank OZK lessened its stake in Aflac Incorporated (NYSE:AFL) by 2.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,800 shares of the financial services provider’s stock after selling 500 shares during the quarter. Aflac comprises 1.0% of Bank OZK’s investment portfolio, making the stock its 26th biggest position. Bank OZK’s holdings in Aflac were worth $2,046,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BKM Wealth Management LLC acquired a new position in Aflac in the fourth quarter valued at about $1,558,000. abrdn plc grew its position in Aflac by 51.2% in the fourth quarter. abrdn plc now owns 298,226 shares of the financial services provider’s stock valued at $24,604,000 after acquiring an additional 100,937 shares during the last quarter. J.W. Cole Advisors Inc. grew its position in Aflac by 353.3% in the fourth quarter. J.W. Cole Advisors Inc. now owns 14,754 shares of the financial services provider’s stock valued at $1,217,000 after acquiring an additional 11,499 shares during the last quarter. Nordea Investment Management AB grew its position in Aflac by 25.9% in the fourth quarter. Nordea Investment Management AB now owns 1,693,249 shares of the financial services provider’s stock valued at $139,676,000 after acquiring an additional 348,400 shares during the last quarter. Finally, G&S Capital LLC grew its position in Aflac by 65.1% in the fourth quarter. G&S Capital LLC now owns 31,825 shares of the financial services provider’s stock valued at $2,626,000 after acquiring an additional 12,551 shares during the last quarter. Institutional investors and hedge funds own 67.44% of the company’s stock.

Insider Transactions at Aflac

In other news, Director Arthur Reginald Collins sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $79.73, for a total transaction of $239,190.00. Following the transaction, the director now directly owns 5,592 shares of the company’s stock, valued at $445,850.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Arthur Reginald Collins sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $79.73, for a total transaction of $239,190.00. Following the transaction, the director now directly owns 5,592 shares of the company’s stock, valued at $445,850.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Masatoshi Koide sold 30,493 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $79.91, for a total value of $2,436,695.63. Following the transaction, the director now directly owns 86,090 shares in the company, valued at $6,879,451.90. The disclosure for this sale can be found here. Insiders have sold 46,493 shares of company stock valued at $3,765,706 over the last ninety days. 0.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

AFL has been the topic of a number of recent analyst reports. Wells Fargo & Company decreased their target price on Aflac from $83.00 to $81.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 11th. UBS Group lifted their target price on Aflac from $80.00 to $84.00 and gave the company a “neutral” rating in a research report on Wednesday, January 10th. Evercore ISI cut Aflac from an “in-line” rating to an “underperform” rating and boosted their price target for the stock from $76.00 to $78.00 in a report on Thursday, January 4th. The Goldman Sachs Group boosted their price target on Aflac from $61.00 to $75.00 and gave the stock a “sell” rating in a report on Tuesday, January 9th. Finally, Keefe, Bruyette & Woods boosted their price target on Aflac from $83.00 to $87.00 and gave the stock a “market perform” rating in a report on Wednesday, April 10th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $82.15.

Aflac Trading Down 0.1 %

AFL traded down $0.12 during trading on Friday, hitting $83.61. The company’s stock had a trading volume of 1,839,028 shares, compared to its average volume of 2,169,786. Aflac Incorporated has a twelve month low of $64.10 and a twelve month high of $86.26. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.33. The stock’s fifty day moving average price is $82.69 and its 200-day moving average price is $81.75. The firm has a market capitalization of $48.11 billion, a P/E ratio of 10.78, a PEG ratio of 2.30 and a beta of 0.91.

Aflac (NYSE:AFL) last issued its quarterly earnings results on Thursday, February 1st. The financial services provider reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.47 by ($0.22). Aflac had a net margin of 24.92% and a return on equity of 17.59%. The business had revenue of $3.78 billion during the quarter, compared to analyst estimates of $4.44 billion. During the same period last year, the firm posted $1.29 earnings per share. Analysts anticipate that Aflac Incorporated will post 6.41 EPS for the current year.

About Aflac

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.